Jazz Pharmaceuticals Hits New 52-Week High of USD 261.07

Jazz Pharmaceuticals Plc has reached a significant milestone by hitting a new 52-week high of USD 261.07 on July 28, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable 135.73% increase over the past year, significantly outperforming the S&P 500's 16.26% gain during the same period. With a market capitalization of USD 11,246 million, Jazz Pharmaceuticals has shown impressive financial metrics, including a price-to-earnings ratio of 18.00 and a return on equity of 14.85%. The company has consistently reported positive results, with net profit for the latest quarter reaching USD 301.43 million, reflecting a staggering growth of 398.01%. Additionally, the inventory turnover ratio stands at a healthy 2.59 times, indicating efficient management of resources. The stock's performance is further bolstered by high institutional holdings at 100%, suggesting strong confidence among major investors. Overall, Jazz Pharmaceuticals continues to solidify its position in the market, showcasing a blend of growth and stability in its financial performance.